Clinical Report: Amyloid-Targeting Therapy and Antiplatelet Use in Alzheimer's Disease
Overview
This report examines the intersection of amyloid-targeting therapies (ATT) and antiplatelet use in Alzheimer's disease (AD), highlighting the potential risks of amyloid-related imaging abnormalities (ARIA) associated with concomitant antiplatelet treatment. The findings underscore the need for careful patient selection and monitoring in clinical practice.
Background
Alzheimer's disease affects millions globally, with amyloid-targeting therapies emerging as a treatment option. However, the risk of ARIA, particularly in patients on antiplatelet therapy, raises significant safety concerns. Understanding the implications of these therapies is crucial for optimizing patient outcomes and minimizing adverse effects.
Data Highlights
No numerical data available in the source material.
Key Findings
Approximately 2.2 million in the US and ~5.9 million in the EU may be eligible for ATT.
APOE ε4 carriers are at higher risk for ARIA, particularly ARIA-H.
Patients with a history of cerebrovascular events are often excluded from ATT trials.
Concomitant antiplatelet therapy may increase the risk of ARIA-H in patients receiving ATT.
Clinical trials show varying rates of intracerebral hemorrhage (ICH) associated with antithrombotic use in ATT-treated patients.
Current guidelines emphasize the need for MRI monitoring in patients on ATT.
Clinical Implications
Clinicians must carefully evaluate the risks and benefits of prescribing antiplatelet therapy in patients undergoing amyloid-targeting treatment. Regular MRI monitoring is recommended to detect ARIA early, particularly in high-risk populations such as APOE ε4 carriers.
Conclusion
The intersection of amyloid-targeting therapies and antiplatelet use presents a complex clinical dilemma that necessitates further research and careful patient management to ensure safety and efficacy.
